New Jersey

Celltrion USA is planning to acquire and expand Eli Lilly and Co.’s biopharmaceutical plant in Branchburg. Scope of the estimated $630-million project is being developed but could include construction and modification of building space; modification of production lines; and purchase and installation of automation, storage, handling, formulation, filling and packaging equipment and systems. The expansion will increase drug substance and drug product production capacity to 135,000 liters per year. Plant acquisition is expected by the end of 2025. Approximately 50% of production lines will continue production of Eli Lilly biologics on a contract basis. Celltrion expects to begin production of its own line of antibody-based biologics for autoimmune and cancer therapies at the site in 2027. Celltrion USA, One Evertrust Plaza, Suite 1207, Jersey City, NJ 07302. IR#NJ250905

Virginia

AstraZeneca is planning to construct an active pharmaceutical ingredients and pharmaceuticals manufacturing plant on a 462-acre site in Albemarle County. Project scope includes construction of multiple buildings with cleanrooms; and purchase and installation of stainless steel tanks and piping, bioreactors, fume hoods and wet laboratory, filtration, testing, sterilization, filling, finishing, labeling, packaging and cold storage equipment. A construction schedule is being developed; the project is expected to be operational in 2029 or 2030. The plant will be used to produce small molecules, peptides, oligonucleotides and antibody drug conjugates to produce oral drug substances for weight and metabolic management, combination small molecule products and oncology indication therapies. AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878. IR#VA251001